Boundless Bio, Inc. Common Stock
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Boundless Bio, Inc. Common Stock generated cash of -$46,855,000, which is less than the previous year. Cash used in financing activities reached the amount of $97,897,000 last year. Net change in cash is therefore $12,782,000.
Cash Flow
| 2016 | -49.01M | -62.04M | 75.36M |
|---|---|---|---|
| 2017 | -84.50M | -33.43M | 120.55M |
| 2018 | -107.97M | -185.04M | 398.46M |
| 2021 | -23.24M | -59.28M | 105.52M |
| 2022 | -39.59M | 16.13M | 126K |
| 2023 | -46.85M | -38.26M | 97.89M |
BOLD Cash Flow Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 11.48M | 34.82M | 11.82M | 38.91M | 36.35M | 72.05M |
Operating activities | ||||||
Net income | -49.43M | -45.90M | -25.21M | -128.82M | -90.23M | -59.66M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 957K | 942K | 682K | 7.45M | 3.74M | 1.57M |
Stock-based compensation expense | 3.33M | 2.29M | 1.15M | 0 | 6.88M | 2.00M |
| Deferred income tax benefit | 3.33M | 2.29M | 1.15M | 0 | 6.88M | 2.00M |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 1.66M | 1.91M | 1.22M | 4.08M | 686K | -671K |
Cash generated by operating activities | -46.85M | -39.59M | -23.24M | -107.97M | -84.50M | -49.01M |
Investing activities | ||||||
Purchases Of Investments | -160.12M | -42.59M | -77.49M | -382.02M | -152.71M | -104.03M |
Investments In Property Plant And Equipment | -633K | -1.06M | -2.03M | -11.60M | -7.55M | -16.65M |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -38.26M | 16.13M | -59.28M | -185.04M | -33.43M | -62.04M |
Financing activities | ||||||
Common Stock Issued | 97.89M | 126K | 105.52M | 14.6M | 39.1M | 75.20M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -144.34M | -38.96M | -36.35M |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 97.89M | 126K | 105.52M | 398.46M | 120.55M | 75.36M |
Net Change In Cash | 12.78M | -23.33M | 22.99M | 105.43M | 2.60M | -35.69M |
Cash at end of period | 24.26M | 11.48M | 34.82M | 144.34M | 38.96M | 36.35M |
| Data source | Data source | Data source |